Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-07-15 Share Issue/Capital Cha…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Correction: SynAct to receive SEK 17.7 million after conversion of warrants
Share Issue/Capital Change Classification · 99% confidence The document is a press release correcting a previous statement regarding a warrant conversion that generated SEK 17.7 million for SynAct Pharma AB. This announcement details a specific financing/capital structure event (warrant conversion) and its immediate financial impact. This fits best under the 'Capital/Financing Update' category (CAP). Although it is a press release, the core subject matter is financing, which is more specific than the general 'Regulatory Filings' (RNS) or 'Report Publication Announcement' (RPA). The document length is relatively short (2868 chars), but it contains the substantive details of the financing event, not just an announcement that a report is attached, thus making CAP the most appropriate classification over RPA/RNS.
2025-07-15 English
Rättelse: SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "Rättelse: SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner" (Correction: SynAct receives SEK 17.7M after conversion of warrants). It details a specific financing/capital structure event: the conversion of warrants resulting in a cash inflow (17.7 MSEK) for the company. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it is a press release, the core content is a financing event, making CAP more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA), especially since it is not merely announcing a report but reporting a material financial transaction. The document length is short (2997 chars), but the content is the primary event itself, not just a pointer to another document.
2025-07-15 Swedish
SynAct tillförs 17,7 MSEK efter konvertering av teckningsoptioner
Capital/Financing Update Classification · 98% confidence The document announces that SynAct Pharma received 17.7 MSEK from the conversion of warrants (teckningsoptioner) by HCM. It details the number of options converted, the resulting cash inflow, the new conversion price, and the resulting share count. This is a specific corporate action related to financing and capital structure changes. Although it involves capital, the core event is the cash inflow from the exercise of options, which fits best under 'Capital/Financing Update' (CAP). The document is short and ends with a link to a PDF, but the content itself is the primary announcement, not just a notice of publication, making CAP more specific than RPA or RNS. The mention of 'teckningsoptioner' (warrants) and the resulting capital injection strongly points to CAP.
2025-07-15 Swedish
SynAct to receive SEK 17.7 million after conversion of warrants
Share Issue/Capital Change Classification · 99% confidence The document announces that SynAct Pharma AB is receiving SEK 17.7 million from the execution of warrants by HCM. This involves a change in capital structure (conversion of warrants into shares) and the resulting change in the number of outstanding shares and share capital. This directly relates to financing activities and capital structure changes. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). Although it is a short announcement, the content is a specific corporate action (warrant conversion proceeds) rather than a general announcement about the publication of a larger report, making CAP more specific than RPA or RNS.
2025-07-15 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage (11.10678%) by an entity (Avanza Bank Holding AB for Avanza Pension) in SynAct Pharma AB, triggered by a 'Nyemission' (New Share Issue). It explicitly reports the number of shares held before and after the transaction, the resulting voting rights, and references specific legal frameworks ('LHF 4 kap. 2§'). This structure is characteristic of a notification regarding a significant change in ownership or voting rights, which aligns with the definition of Major Shareholding Notification (MRQ) or potentially Director's Dealing (DIRS) if the holder were an insider, but since it is a major institutional holder reporting a threshold crossing due to a new issue, MRQ is the most appropriate fit among the provided options, as it concerns changes in significant share ownership levels crossing thresholds. The document is a formal filing reporting these figures.
2025-07-11 Swedish
Förändring av antalet aktier och röster i SynAct Pharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly announces a change in the total number of shares and votes ('Förändring av antalet aktier och röster') following a directed share issue ('riktade emissionen'). This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for Share Issue/Capital Change (SHA). Although it is a short announcement, the core content is the capital change itself, not just the announcement of a report, making SHA more specific than RPA or RNS. The text mentions the total number of shares increasing and details about the ongoing registration process.
2025-06-30 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.